Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 6/20 | 0.56 |
| ▸ | MEN1 | O00255 | 4/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.56 |
| ▸ | HTT | P42858 | 3/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | CA1 | P00915 | 1/20 | 0.56 |
| ▸ | MMP2 | P08253 | 1/20 | 0.56 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.56 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.56 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.53 |
| ▸ | RECQL | P46063 | 2/20 | 0.52 |
| ▸ | GAA | P10253 | 2/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.49 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL27844722 | 0.98 | LMNA (0.55) | LMNAMEN1KMT2ASMN1; SMN2HTT | |
| SCHEMBL27039902 | 0.82 | ALDH1A1 (0.55) | LMNAMEN1KMT2ASMN1; SMN2HTT | |
| SCHEMBL7380541 | 0.81 | LMNA (0.56) | LMNAMEN1KMT2ASMN1; SMN2HTT | |
| SCHEMBL31598449 | 0.81 | LMNA (0.56) | LMNAMEN1KMT2ASMN1; SMN2HTT | |
| SCHEMBL2137755 | 0.80 | LMNA (0.55) | LMNAMEN1KMT2ASMN1; SMN2HTT | |
| SCHEMBL584346 | 0.80 | ALDH1A1 (0.73) | LMNAMEN1KMT2ASMN1; SMN2HTT | |
| SCHEMBL461513 | 0.80 | ALDH1A1 (0.61) | LMNAMEN1KMT2ASMN1; SMN2HTT | |
| SCHEMBL11835914 | 0.79 | ALDH1A1 (0.59) | LMNAMEN1KMT2ASMN1; SMN2HTT | |
| SCHEMBL10534498 | 0.79 | HTT (0.71) | LMNAMEN1KMT2ASMN1; SMN2HTT | |
| SCHEMBL6754385 | 0.79 | LMNA (0.54) | LMNAMEN1KMT2ASMN1; SMN2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021011722-A1 | MOLECULES HAVING CERTAIN PESTICIDAL UTILITIES, AND INTERMEDIATES, COMPOSITIONS, AND PROCESSES RELATED THERETO | DOW AGROSCIENCES LLC (US) | 2021-01-21 | — | — | WO | disclosed |
| WO-2020146779-A1 | mTORC1 INHIBITORS FOR ACTIVATING AUTOPHAGY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-07-16 | — | — | WO | disclosed |
| US-9751857-B2 | Hepatitis B antiviral agents | NOVIRA THERAPEUTICS, INC. (US) | 2017-09-05 | — | — | US | disclosed |
| US-9676747-B2 | Hepatitis B antiviral agents | NOVIRA THERAPEUTICS, INC. (US) | 2017-06-13 | — | — | US | disclosed |
| CN-105622426-A | Preparation method of 4-fluoro-N-methyl-3-nitroaniline | ZHEJIANG DINGLONG TECH CO LTD | 2016-06-01 | — | — | CN | disclosed |
| CN-105622426-A | Preparation method of 4-fluoro-N-methyl-3-nitroaniline | ZHEJIANG DINGLONG TECH CO LTD | 2016-06-01 | — | — | CN | disclosed |
| US-9061008-B2 | Hepatitis B antiviral agents | NOVIRA THERAPEUTICS, INC. (US) | 2015-06-23 | — | — | US | disclosed |
| WO-2014024119-A1 | HETEROCYCLIC AMIDES AS ITK INHIBITORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2014-02-13 | — | — | WO | disclosed |
| US-20070082899-A1 | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof | ASTRAZENECA AB (SE) | 2007-04-12 | — | — | US | disclosed |
| US-20070072853-A1 | Benzimidazole derivatives compositions containing them, preparation thereof and uses thereof | ASTRAZENECA AB (SE) | 2007-03-29 | — | — | US | disclosed |
| US-7138420-B2 | Substituted benzimidazole compounds | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2006-11-21 | — | — | US | disclosed |
| US-20050203158-A1 | Substituted benzimidazole compounds | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-09-15 | — | — | US | disclosed |
| EP-1529046-A1 | SUBSTITUTED BENZIMIDAZOLE COMPOUNDS | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2005-05-11 | — | — | EP | disclosed |
| WO-2004014905-A1 | SUBSTITUTED BENZIMIDAZOLE COMPOUNDS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070082899-A1 | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof | F12, H1-3, H1-4 | LMNA 2120/4885MEN1 2645/4885KMT2A 1385/4885 |
| US-20070072853-A1 | Benzimidazole derivatives compositions containing them, preparation thereof and uses thereof | RB1, CYP2C19, ADRB3 | LMNA 1900/4885MEN1 3142/4885KMT2A 1921/4885 |
| US-20050203158-A1 | Substituted benzimidazole compounds | ITK, BLK, SBK1 | LMNA 2269/4885MEN1 4520/4885KMT2A 2504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.